Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 1, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Weiss Amir	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2024	Officer (give title below) Other (specify below) Chief Accounting Officer
(Street) Tel Aviv, L3 6944020 (City) (Zip) (State)	4. If Amendment, Date Original Filed (Month/Day/Year)	(6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	Execution Date, if Code						(A) or Disposed of (D) Owned Following Reported		Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
									or Indirect (Instr. 4)
						(A) or
			Code		Amount	D	Price		(Instr. 4)
'Ordinary Shares (1)	02/28/2024		M		3.219	A	(2)	13,895	D

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Title of	2	3. Transaction	3A. Deemed	5. Number 4.		6. Date Exercisable		7. Title and Amount			8. Price of 9. Number of	10.	11. Nature
Derivative	Conversion Date		Execution Date, if Transaction of			and Expiration Date		of Underlying			Derivative Derivative	Ownership of Indirect
Security	or Exercise	(Month/Day/Year) any		Code Derivative		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year) (Instr. 8)	Securities				(Instr. 3 and 4)		(Instr. 5)	Beneficially		Derivative Ownership
	Derivative			Acquired						Owned	Security:	(Instr. 4)
	Security				(A) or						Following	Direct (D)
						Disposed						Reported	or Indirect
						of (D)							Transaction(s) (1)
					(Instr. 3, 4,								(Instr. 4)	(Instr. 4)
					and 5)
											Amount
											Or
								Date Exercisable Date	Expiration	Title	Number
											of
				Code		(A)	(D)				Shares
Restricted										Ordinary
Share	(2)	02/28/2024		M			3,219	(3)	(3)	Shares	3,219	\$ 0	0	D
Units										(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unitingent right to receive, at settlement, one ordinary share or, at the Human Resources and Committee, the cash value of one ordinary share.

3. Restricted share units were granted on February 2, 2021, February 28, 2021, February 28, 2022, February 28, 2024,

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss 03/01/2024

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of inform are not required to respond unless the form displays a currently valid OMB Number.